Microarray-Tumor Reveal® FFPE

TEST: 512014
Test number copied
CPT: 81277
Updated on 12/4/2024
Print Share

Synonyms

  • aCGH
  • CGH
  • CMA
  • Microarray Oncology
  • Reveal® SNP Array
  • WGA

Special Instructions

Pertinent medical findings should accompany the test request form. If prior FISH analysis has been performed, include copy of report. Please direct questions to genetic customer service at 800-345-4363.

This assay currently is not available in New York state.

Pertinent medical findings should accompany the test request form. If prior FISH analysis has been performed, include copy of report. Please direct questions to genetic customer service at 800-345-4363.

<.

Pertinent medical findings should accompany the test request form. If prior FISH analysis has been performed, include copy of report. Please direct questions to genetic customer service at 800-345-4363.

This assay currently is not available in New York state.

Expected Turnaround Time

12 - 15 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Specimen Requirements

Specimen

Formalin fixed paraffin embedded (FFPE) tissue

Volume

One paraffin block or ten 10-micron thick section slides

Minimum Volume

Sufficient sample to obtain enough DNA to run microarray

Container

Paraffin block transport pouch

Collection

FFPE specimen should be fixed in 10% neutral-buffered formalin or formaldehyde.

Storage Instructions

Room temperature

Causes for Rejection

Improperly embedded preparation; decalcified bone or bone core

Test Details

Use

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

Limitations

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only contain heterochromatin or tetraploidy. Genotypes in some formalin-fixed tissues are unable to be determined, allowing only genomic dosage to be determined.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Methodology

SNP Microarray analysis is performed using the Oncoscan® FFPE platform, which uses more than 220,000 SNP probes with a median spacing of 5.0 kb, within the majority of genes.

References

Nauen D, Haley L, Lin MT, et al. Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas. Brain Pathol. 2016 Mar;26(2):206-214.26206478

LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf